New drug substantially extends survival in pancreatic cancer

Sep 16, 2008

A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

European investigators led by Prof. Matthias Löhr from the Karolinska Institute evaluated the efficacy and safety of three different doses of cationic lipid complexed paclitaxel (EndoTAG-1) administered twice weekly, in combination with weekly infusions of gemcitabine, compared to gemcitabine alone, in 200 patients with pancreatic adenocarcinoma.

"EndoTAG consists of charged particles that bind preferentially to the fast-growing endothelial cells in new blood vessels being formed by tumors," Prof. Löhr explained. "The drug, paclitaxel, is then released and thus directly reaches an important target in tumors, i.e. the vessels. Paclitaxel itself is not very efficient in pancreratic cancer."

After following patients for a year, the researchers found that treatment with such combination led to a substantially extended median survival time compared to standard therapy. Patients given gemcitabine alone survived on average 7.2 months, compared to up to 13.6 months for patients who received repeated doses of the combination (EndoTAG plus gemcitabine).

"These results are the best I have ever seen in palliative treatment in pancreatic cancer," Prof. Löhr said. "The results are really excellent and a phase III study is in the making."

Source: European Society for Medical Oncology

Explore further: Pain and itch may be signs of skin cancer

add to favorites email to friend print save as pdf

Related Stories

Awarded a Pell Grant? Better double-check

19 minutes ago

(AP)—Potentially tens of thousands of students awarded a Pell Grant or other need-based federal aid for the coming school year could find it taken away because of a mistake in filling out the form.

Facebook shares profit growth story

20 minutes ago

Facebook on Wednesday reported that is quarterly profit more than doubled amid big gains in ad revenues and a jump in users.

Six charged in global e-ticket hacking scheme

48 minutes ago

Criminal charges were filed Wednesday against six people in what authorities said was a global cyber-crime ring that created fraudulent e-tickets for major concerts and sporting events.

EU sets new energy savings target at 30%

58 minutes ago

After months of tough negotiations, the European Commission recommended Wednesday a new energy savings target of 30 percent so as to combat climate change and ensure self-sufficiency.

IHEP in China has ambitions for Higgs factory

58 minutes ago

Who will lay claim to having the world's largest particle smasher?. Could China become the collider capital of the world? Questions tease answers, following a news story in Nature on Tuesday. Proposals for ...

Recommended for you

Incomplete HPV vaccination may offer some protection

45 minutes ago

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. These findings appear in the journal ...

New imaging agent provides better picture of the gut

50 minutes ago

A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time ...

User comments : 0